6533b851fe1ef96bd12a8e5d

RESEARCH PRODUCT

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction

Patricia PalauJulio NúñezHector MerencianoGema MiñanaJosep LupónRafael De La EspriellaMartina AmiguetJuan SanchisRaquel HerediaAntoni Bayes-genisEnrique SantasFrancisco J. Chorro

subject

heart failure with preserved ejection fractionmedicine.medical_specialtylcsh:Medicinerisk stratification030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterymedicine030212 general & internal medicineStage (cooking)right ventricularStaging systemRisk stratificationRight ventricularbusiness.industryMortality ratelcsh:RGeneral Medicinemedicine.diseaseBlood pressureHeart failure with preserved ejection fractionHeart failurePulmonary arteryRisk stratificationCardiologybusinessHeart failure with preserved ejection fraction

description

Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP &ge

yearjournalcountryeditionlanguage
2020-03-18
10.3390/jcm9030831https://ddd.uab.cat/record/252514